According to industry reports, Indian pharmaceutical companies are expected to achieve an 11% growth in both sales and EBITDA in the first quarter of the fiscal year 2026.
Key highlights:
• Anticipated 11% growth in sales and EBITDA for the Pharma sector.
• Positive outlook for financial performance in Q1FY26.
• Reflects resilience and potential growth in the Indian pharmaceutical industry.
This development underscores the steady growth and resilience of the Indian pharmaceutical sector amidst evolving market dynamics, offering potential investment opportunities for stakeholders in the Indian business landscape.
Source: Latest Business News Today: Stock Markets, Financial News, India Business & World Business News